SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 10th, 2020 • Zanganeh Maky • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 6, 2020 by and among Summit Therapeutics Inc., a Delaware corporation, with its principal place of business at One Broadway, 14th Floor, Cambridge, MA 02142 (the “Company”), and the investor named on Exhibit A hereto (the “Investor”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • January 23rd, 2020 • Zanganeh Maky • Pharmaceutical preparations • New York
This Stock Purchase (this “Agreement”) is dated as of December 24, 2019, and entered into between Robert Duggan, an individual (the “Seller”) and each of the parties listed on Exhibit A hereto (each such party, a “Buyer”, and each of the Buyers and the Seller, a “Party” to this Agreement, and collectively, the “Parties”) for the purchase of certain equity interests of Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the “Company”).
ContractZanganeh Maky • September 28th, 2020 • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE WARRANT SHARES TO BE ISSUED UPON ITS EXERCISE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH HEREIN, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
DATED [•], 2020 SUMMIT THERAPEUTICS INC. and [CONSULTANT] WARRANT AGREEMENTWarrant Agreement • September 28th, 2020 • Zanganeh Maky • Pharmaceutical preparations • Delaware
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 10th, 2020 • Zanganeh Maky • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 6, 2020 by and among Summit Therapeutics Inc., a Delaware corporation (the “Company”), the investor named in that certain Securities Purchase Agreement, dated November 6, 2020 by and between the Company and Polar Capital Funds plc – Biotechnology Fund, and the investor named in that certain Securities Purchase Agreement, dated November 6, 2020 by and between the Company and Mahkam Zanganeh Revocable Trust (each a “Purchase Agreement” and together the “Purchase Agreements”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreements unless otherwise defined herein.
JOINT FILING AGREEMENTJoint Filing Agreement • September 28th, 2020 • Zanganeh Maky • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01 per share, of Summit Therapeutics Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • January 23rd, 2020 • Zanganeh Maky • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Ordinary Shares, par value £0.01 per share, of Summit Therapeutics PLC, a foreign private issuer incorporated in England and Wales. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
